 MDACC# 2010- 0794  
Version Date: 6.13.17  
COVER P AGE 
MDACC #: 2010-0794  
Phase II Shor t-term Adjuv ant The rapy  and Biomark er stud ies with target ed agents in Women 
with Es troge n Receptor Negat ive Breast Cancer 
Principal Investigators: Banu Arun, M.D.  
The Univers ity of Texas M .D. Anderson C ancer Cente r 
Telephone: 713-792-2817 
Fax: 713-563-0910 
E-mail ad dress: barun@mdanderson.o rg 
Victori a Seewa ldt, M.D. 
Duke University 
Telephone: 919-668-2454 
E-mail ad dress: seew a001@m c.duke.edu  
Dihua Yu, M.D.  
The Univers ity of Texas M .D. Anderson C ancer Cente r 
Telephone: 713-792-3636 
E-mail ad dress: dyu@mdanderson.org  
Collabo rators: Yun Gong, M.D. 
The Univers ity of Texas M .D. Anderson C ancer Cente r 
Telephone: 713 563 5625 
Fax: 713 563 5664 
E-mail ad dress: ygon g@m dand erson.o rg 
Neil Spector, M.D. 
Duke Uni versi ty 
Telephone: 919 681 4699 
Statistician: Diane D Liu. 
The Univers ity of Texas M .D. Anderson C ancer Cente r 
Telephone: 713-794-4175 
Fax: 713-563-4242 
E-mail ad dress: dliu@mda nderson.org  
Proprietary Information of MD Anderson
ii   MDACC# 2010- 0794  
Version Date: 6.13.17  
  
 
SCHE MA 
 
 
Phase II Short- term Adjuv ant Therapy and B iomark er stud ies w ith target ed agents in Wo men wi th 
Estrogen R eceptor Nega tive Bre ast Canc er 
 
 
Study  Populat ion: Women his tory o f ER neg ative breast can cer 
 
 
  
Med ical history,  (physical exam), blood  
 
   
Sign co nsent 
 
 
 
 
Basel ine rand om periareolar br east fine n eedle aspi ration (RPF NA), research  blood  
  
 
 
 
Rand omize, on study for 3 mon ths (+/- 7 days) 
 
Month 3 periare olar bre ast fine n eedle asp iration, research blood 
Endpoint s: Prim ary: Cha nges in Ki- 67 
Secondar y: Changes in cytology, proli feration, apo ptosis in breast tissue (p-Y 418-Src, p-Y-118- 
Paxil lin, (and  mark ers identified in Ai ms 1 and 3 of the g rant), CC3, bcl-2, EGFR, P-EGFR, IG F 
pathway in  serum) 
 
Toxicity assessment  
Proprietary Information of MD Anderson
   MDACC# 2010- 0794  
Version Date: 6.13.17  
  
 
TABLE OF CON TENTS  
 
Page 
COVER P AGE ............................................................................................................................................. i  
SCHE MA ..................................................................................................................................................... ii 
TABLE OF CON TENTS  ........................................................................................................................... iii  
1. OBJECT IVES 
1.1 Primary O bjective ...................................................................................................................... 1 
1.2 Seconda ry Objec tives ................................................................................................................ 1 
2. BACKGROUND ................................................................................................................................... 1 
2.1 Breast Can cer Chem oprevention and Chem oprevention Ag ents .............................................. 1 
2.2 Dasatinib as Chem opreventive Ag ent for B reast Cancer .......................................................... 1 
2.3 Tissue Acq uisition Methods ...................................................................................................... 8 
3. SUMMARY OF S TUDY PLAN  8 
4. PARTICIPANT SE LECTION  ............................................................................................................ 9 
4.1 Inclusion C riteria ....................................................................................................................... 9 
4.2 Exclu sion Crite ria .................................................................................................................... 10 
4.3 Inclusion o f Wo men and Minorities ........................................................................................ 11 
4.4 Recruitment and Ret ention Plan .............................................................................................. 11 
5. AGENT AD MIN ISTRATION  
5.1 Dose Regimen and D ose Groups ............................................................................................ 12 
5.2 Study Ag ent Adm inistration ................................................................................................... 12 
5.3 Run-In Procedur es .................................................................................................................. 12 
5.4 Proh ibited Therapies ............................................................................................................... 12 
5.5 Restricted Therapies ................................................................................................................ 13 
5.6 Concom itant Medications ....................................................................................................... 14 
5.7 Dose Mo dificat ions ................................................................................................................. 14 
5.8 Adherence/Com plian ce ........................................................................................................... 14 
6. PHA RMACEUT ICAL IN FOR MATION ......................................................................................... 15  
6.1
 Study Ag ent ............................................................................................................................. 15 
6.2 Rational e for Dos e Selection ................................................................................................... 16 
6.3 Avai lability .............................................................................................................................. 16 
6.4 Agent Account ability .............................................................................................................. 16 
6.5 Packaging and Labeling .......................................................................................................... 17 
6.6 Storage .................................................................................................................................... 17 
6.7 Registration / Randomization .................................................................................................. 17 
6.8 Registration / Randomization .................................................................................................. 17 
6.9 Blinding and Unb linding Methods .......................................................................................... 18 
6.10 Agent D estruction/Disposal ..................................................................................................... 18 
7. CLINICAL EVALUATION S AND PROCE DUR ES 
7.1 Schedule of Events ................................................................................................................... 18 
7.2 Baseline Testing/Prestudy Evaluat ion ....................................................................................... 18 
7.3 Evaluat ion Dur ing Study In tervention ...................................................................................... 19 
Proprietary Information of MD Anderson
   MDACC# 2010- 0794  
Version Date: 6.13.17  
 7.4 Evaluat ion at Com pletion o f Interv ention ................................................................................. 19 
7.5 Methods for C linical Procedures ............................................................................................... 19 
8. CRITERIA F OR EVALUATION AN D ENDPOINT DEF INITION ............................................ 24 
8.1 Primary Endpoin t  ................................................................................................................... 24 
8.2 Seconda ry Endpoi nts  .............................................................................................................. 24 
8.3 Off Ag ent Criter ia ................................................................................................................... 24 
8.4 Off Study Criteria  ................................................................................................................... 24 
9. SPEC IMEN MANAG EMENT  ......................................................................................................... 25 
9.1 Laborato ries  ............................................................................................................................ 25 
9.2 Collection and handl ing proced ures  ....................................................................................... 25 
9.3 Tissue Ban king  ....................................................................................................................... 26 
10. REPOR TING  ADV ERSE EVENTS   ................................................................................................ 26 
10.1 Adverse Events  ........................................................................................................................  26 
10.2 Serious Ad verse Events  ........................................................................................................... 27 
11. STUDY MONITO RING   ................................................................................................................... 28 
12. STAT ISTICAL CON SIDERA TIONS   ............................................................................................. 28 
13. ETHIC AL AN D RE GULATORY CON SIDERATIONS   ............................................................... 30 
13.1 Form FDA 1572 ....................................................................................................................... 30 
13.2 Other Required Docum ents  ..................................................................................................... 30 
13.3 Institutional Rev iew Board App roval  ...................................................................................... 30 
13.4 Inform ed Consent  .................................................................................................................... 31 
13.5 Other  ........................................................................................................................................ 31 
REFERE NCES  ......................................................................................................................................... 32 
Proprietary Information of MD Anderson
1   M D A C C # 2 0 1 0 -0 7 9 4  
  V ersi o n D at e: 6. 1 3 . 1 7  
  
1.  O B J E C T I V E S  
 
 
O verall o b j ecti v e is t o e val uate t he  c he mo pre ve n ti v e p o te nti al  of dasa ti ni b  i n a p hase II s h ort ter m 
a dj u v a nt  a n d b i o mar k er  st u d y, b y e val uati n g it s b i o mar k er  m o d ulat o r y  eff ic ac y  i n  brea st  ti ss ue  a n d se ru m 
of w o m e n at  i nc rea se d r is k  f or sec o nd p ri mar y brea st ca ncer. 
 
1. 1.  Pri mar y O bj ec ti ve 
 
T o e val ua te t he a bili t y  o f tr eat me nt  wi t h dai l y  dasa ti ni b t o decr ea se p r olifera ti o n  of hi g h r is k  br east 
e p it h eli al cel ls  o n c o ntr al at eral ra n d o m periare ola r fi n e nee dle  as pir ati o n ( R P F N A) i n pat ie nts w it h 
brea st  ca n cer  t h at d o n ot o ver e x pre ss  est r o ge n re ce pt or  ( E R ).  We wi ll  e val ua te pre- a n d p ost dasat i n i b 
tr eat m e nt  Ki - 6 7 i n sa m ples  o btai ne d v ia  F N A fr o m  bre ast  ti ss ue  of w o m e n at  hi gh ris k  f or sec o n d 
pri mar y brea st c a nc er.  T h is  s pecif ic ai m  tes ts t he h y p ot hesi s t h at  treat m e nt  w it h  da sa ti n i b will i n d uc e a 
decr ea se i n  pr olife ra ti o n. 
 
1. 2.  Sec o n dar y O bj ec ti ves: 
 
 
1)  T o e val uate dasati n i b  i n d uce d m o d ula ti o n  of c y t ol o g y , ot her  p r o lifer at i o n a n d a p o pt osi s mar kers i n 
hi g h ris k  br ea st tiss ue ( p- Y 4 1 8- Src, p - Y- 1 1 8- Pa xill i n, e p i der m al  g r o wt h fac t or  re ce p t o r ( E G F R), 
p h os p h or y la te d E G F R  ( P- E G F R), b ce ll  l y m p h o m a 2 ( bcl- 2), clea v e d ca s pase 3 ( C C 3,)) b y 
i m m u n o hist oc he m is tr y  (I H C) a n d b y di re ct p r o te o mic  pr ofili n g met h o ds (a s w ell  as  n o v el  mar ker s 
i de ntifie d i n Ai ms 1 a n d 3 of t he gra n t: I G F- 1, I G F B P 1 a n d 3).  
 
2)  T o e val uat e da sati n i b  i n d uce d m o d ula ti o n  of bi o mar k er  i n t h e ser u m  i nc lu di n g ins u li n li k e gr o wt h 
fa ct or  (I G F) pat h w a y  
 
3)  T o a ss ess  t o xici t y  of da sati ni b i n  t h is p atie nt p o p ula ti o n  
 
2.  BA C KG R OU N D A N D R A TI O N A L E  
 
2. 1 Bre ast  C a ncer  C he m o pre ve nt io n a nd C he m o pr e v ent io n A g e nts  
 
Ta m o xife n i s c urr e n tl y  t he o nl y F D A a p pr o ve d a g e nt  f or t h e p re v e n ti o n of br ea st ca nc er in hi g h ris k 
w o m e n ( 1 ). T he Na ti o nal  A dj u va nt Br ea st a n d B o w el  Pr oj e ct  ( N S A B P ) c o n d ucte d a lar ge- sca le, d o u b le 
bli n d, p ha se II I breast  ca nc er  pre v e n ti o n tri al  P 1 ( B C P T- P 1) usi n g ta mo xi fe n vers us pl ace bo i n  1 3, 3 8 8 
w o m e n at  hi g h r is k  f or bre ast  ca ncer ( 2). Af te r a me d ia n f oll o w- u p of 5 4 m o nt hs, a 4 9 % re duc ti o n i n  t he 
i n ci de n ce of i n vasi v e b rea st  ca nc er ( p 0. 0 0 0 0 1 ) o cc u rr e d a m o n g  t h ose recei vi n g ta m o xife n ( 1).  S i de 
eff ec ts s ee n wi t h  ta m o xife n use inc lu de d  i n cre ase d  ri s k  of t h r o m b oe m b olic e ve n ts,  ute ri ne ca nce r, a n d 
me n o pa usal s y m pt o ms. F urt her m ore, re d ucti o n s ee n  i n  brea st  ca n cer  i n ci de nce wa s o nl y i n E R  p osi ti ve 
t u mors;  ta m o xife n  di d not  re d uce t he i n ci d ence of E R  ne gati v e b rea st ca nc er. E R  ne gati v e b rea st ca nc ers 
occ ur m ore i n pre- m e n o pa usal  w o me n a n d a re  ass ociat e d wi th a g g ress i v e be ha vi or a n d p o or pr o gn os tic 
fe at u res  ( 3),  ( 4).  U nf o rt unatel y, c ur re ntl y  t h ere  are n o n o n- h or m o nal a g e n ts a vaila b le  a n d a p p r o ve d  f o r  
t he p re ve n ti o n of E R  ne ga ti ve ca nce r. F u rt h er m ore, t he re is a nee d  f or  le ss  t o x ic a ge n ts.  Se veral c las ses of 
c o m m o nl y use d dr u g s a n d  n o v el  a g e n ts,  s uc h  as N S AI D s, re ti n oi d s, or nit hi n e d ec ar b o x yla se  i n hi bi t o rs,  3- 
h y dr o x y- 3- met h yl g l uta r yl c oe nz y m e A ( H M G- C o A) re d ucta se  i n hi b it o rs (st at i n s), a n d s rc in hi bi t o r, ar e 
p ote nti al  a g e n ts f or  i n ves ti gati o n f or bre ast  c a n cer  p re ve n ti o n Pr o pri et ar y I nf or m ati o n of M D A n d er s o n 
2   MDACC# 2010- 0794  
  Version Date: 6.13.17  
 2.2   Dasatinib as a Chemopreventive Agent for Breast Cancer 
Preclinical studies: 
 
The stero id receptor co-activat or (S rc) pathway shares a common pathw ay with A MPK  via mammalian 
target of rapamycin (mTOR). c- Src (Src ) belongs to the Src  family non- recep tor ty rosine kinas es. All Src 
family mem bers share st ructural sim ilarities: 1) a c-terminal tail containing a nega tive-regulatory Y residue 
(Y527 ); 2) Src ho mology domai ns (SH2 and SH 3) and S H1 k inase do main containing an 
autophosph orylation si te (Y416) f or maximal kinase activ ity; and 3) a N-terminal domain (SH4) for 
myrisylation and mem brane bin ding (5 ). EG FR and HER2, sim ilar to other growth facto r receptors, ca n 
bind to and ac tivate Src  (6). Src is involved i n multiple tumorigenesi s processes ( 7).  Src o v erexpr ession 
(Src+) and a ctivation w as detec ted in > 80% of  ductal carcinoma in si tu (DCIS) lesion s and  correlated w ith 
HER2 expression ( 7), (8).   In our pre liminary data, Src+ and ac tivation w as detected in 10% (1 /10) 
patients with breast hype rplasia, 50% (3/6) patients with high-g rade aty pia, 80% (4/5) patients with E R- 
high g rade a typia. Sr c+ als o correlated with HER2+, a nd Src phosphoryla tion on Y416 (p-Y-416, 
indica ting activation) pr edicted ER  negativity/Ta moxifen resistance (TamR). The reverse relationship 
betwee n Src  and ER is cons istent with previous r eports that Src  promoted estrogen depend ent ERalph a 
degradation ( 9).  Sr c activation ha s also b een o bserved in TamR brea st cancer cells and Sr c inhibitor 
(AZD0530) supp ressed the invasion  of TamR ce lls (10). Thes e findings hi ghlight a key role for S rc in 
receptor tyrosine kinase  (RTK) signaling, and in ER- brea st cancer developm ent. There fore, inhibiting sr c 
pathw ay may present  an e ffectiv e way  to prev ent breast can cer. 
 
Dasatinib is a pot ent, broad spectrum ATP-competi tive in hibitor of 5 crit ical oncogen ic tyrosine 
kinase /kinase fam ilies: BCR-AB L, SRC, c-KIT, PDGF receptor β (PDGFRβ), and ephr in (EPH) receptor 
kinases,  each of which has been  link ed to multiple forms of hum an malig nanc ies. Drug disco very and 
nonclin ical pharm acolo gy stud ies show ed that dasatinib (Sprycel (dasatinib) BMS-354825 B-MSIB, versi on 
#5, 2006) i nhibit proli feration o f cance r cell lin es that express activated s rc and c-kit. 
 
 
Clinical Exp erience with dasatinib: 
 
Four s ingle-arm m ultice nter studi es were conduc ted to determ ine the eff icacy and safety of dasatinib in 
patients with CML or Ph iladelphia ch romosome-positive ac ute lymphoblast ic leukemia (Ph+  ALL ) resistant 
to or in tolerant of treatm ent with imatinib. R esistance to imatin ib included failure to achieve a complete 
hemat ologic response (within 3–6 months) or maj or cytogenetic response (by month 12) or pro gression 
of disease after a previous c ytogenetic or hematolog ic response. Imat inib i ntolerance include d ina bility to 
tolerate 400 mg or m ore of imatin ib per day or discontinuation of imat inib because of to xicity. The st udies  
are ong oing. The re sults are ba sed on a m inimum of 6 months follow-up after the sta rt of das atinib 
therapy. Mo st pati ents had long dis ease h istories with ex tensive prior treatm ent, including imatinib, 
cytotoxic chem otherapy, inte rferon, and stem cell transplant. The m aximum imat inib dose h ad been 400–
600 mg/day in about one-half of the patients and >6 00 mg/day in the other ha lf (SPRYCEL ® (da satinib) 
Table ts Prescribing I nformation.Bristol- Myers S quibb Com pany  P, NJ. June 20 06). All pati ents were t reated 
with dasatinib 70 mg BID on a continuous bas is. The median durations of treatm e nt was betw een 2.8 
- 5.6 months SPRYCE L® (dasatinib) Ta blets  Presc ribing Information. B ristol -Myers Squibb Company P, 
NJ. June 2006 ). 
 
The primary ef ficacy endpoint in chronic phase CML was major cy togenet ic response (MC yR), defined as 
elimination (complete cytogenetic  respons e, CCyR) or subs tantial diminution (by at least 65%, partial 
cytogenetic  response) of Ph+ hematopoiet ic cells. The primary endpoint in accelerated pha se, myel oid 
blast p hase, and lymphoid bla st phase CML, and Ph+ A LL w as major hematolog ic respon se (MaHR), 
defined as either a complete hematolog ic respons e or no evidence of leukemia as defined in Table 1. 
Proprietary Information of MD Anderson
3   MDACC# 2010- 0794  
  Version Date: 6.13.17  
  
Most cy togenetic responses occu rred after 12 w eeks of treatment, when the first cytogenetic analyse s 
were performed. Hematol ogic and cytogenetic r esponses were stable du ring the 6-month follow-up of 
patients with chronic phas e, accelera ted phase, and myel oid blast phase CML. The m edian durations o f 
major he matologic response wer e 3.7 m onths in lymphoid bla st CML and 4.8 mo nths in Ph+ ALL. There 
were no age- or gender- related r esponse differences (SPRYCEL® (d asatinib) Table ts Pre scribing 
Information.  Bristol-Myers Squibb Com pany  P, NJ. June 2006) 
 
Table 1: Efficacy  in Dasa tinib Cl inical Stu dies (All Treated Popu lations)a 
  
Chronic 
(n=186)  
Accelerated 
(n=107) Mye loid 
Blast 
(n=74) Lymp hoid 
Blast 
(n=42)  
Ph+ ALL 
(n=36) 
Hemato logic Response  Rateb (%) 
MaHR (9 5% CI) n/a 59 (49–68)  32 (22–44)  31 (18–47)  42 (26–59)  
CHR (95% CI) 90 (85 –94) 33 (24 –42) 24 (15 –36) 26 (14-42) 31 (16 –48) 
NEL (95% CI) n/a 26 (18 –36) 8 (3–17) 5 (0.6 –16) 11 (3.1 –26) 
Cytogenetic Respo nsec (%) 
MCyR (95% CI) 45 (37–52)  31 (22 –41) 30 (20 –42) 50 (34 –66) 58 (41 –74) 
CCyR (95% CI) 33 (26 –40) 21 (14 –30) 27 (17 –39) 43 (28 –59) 58 (41 –74) 
a Numbers in bold font are the results of primary endpo int. 
b Hemat ologic response crite ria (all respons es conf irmed af ter 4 weeks): 
Majo r hematolog ic response: (MaHR) = complete hemato logic response (CHR) + no ev idence of 
leukemia (NEL ). 
CHR (chronic CML): WB C ≤ institutional ULN, platele ts <450,000/ mm3, no blast s or 
promyelocy tes in peripheral blo od, < 5% myelocy tes plus metamyel ocytes in pe ripheral blood, 
basophil s in per ipheral b lood ≤ institutional ULN, and no ext ramedul lary involvement. 
CHR (advanced CML /Ph+  ALL ):  WBC ≤ institutional ULN, AN C ≥ 1000/mm3, 
platele ts ≥ 100,000/mm3, no blas ts or promyelocy tes in peripher al blood, b one marrow 
blasts ≤ 5%, <5% myel ocytes pl us metamyelocy tes in  peripheral blood, b asophils in 
peripheral blood ≤ institut ional ULN, and no extramedull ary involvem ent. 
NEL : same cr i teria as for CHR but AN C ≥ 500/mm3, <1000/mm3 and/ or platele ts ≥ 20,000/mm3 
and ≤ 100,000/mm3. 
c Cytogenetic response criter ia: complete (0% Ph+ meta phases) or partial ( >0%–35 %). MCyR (0 %– 
35%) combines b oth complete and partial r esponses. 
 
n/a =  not applicable. 
 
Safety of da satinib in clinic al studies 
 
The below da ta reflect exposure to dasat inib in 911 patients with leukemia from  1 Phase I and 5 Phase  II 
clinic al studie s. The m edian duratio n of therapy was 6 mo nths (range 0– 19 month s). 
 
The majori ty of dasat inib -treated  patients exper ienced adverse drug reactions at some time. Drug was 
discontinued for adverse drug reactions in 6% of patients in chronic phase CML, 5% in accelera ted phase 
CML, 11% in myeloid b last pha se CML, and 6 % in l ymphoid blast ph ase C ML or Ph+ ALL. 
 
The m ost frequent ly reported serious adverse ev ents (SAEs) included pyrexia (9%), pleural e ffusion 
(8%), febrile neutrope nia (7%),  gastrointestinal bleeding (6%),  pneumonia (6 %), thrombocytopenia (5%), 
dyspnea (4%) , a nemia (3%), cardiac fail ure (3%),  and diarrhea (2% ). 
Proprietary Information of MD Anderson
4   MDACC# 2010- 0794  
  Version Date: 6.13.17  
  
All treatm ent-emerg ent adverse ev ents (excluding l aboratory abnormalit ies), regardless of relationsh ip to 
study drug, that were reported in at least 20% of the pat ients in dasatin ib clinical studies are shown in 
Table 2. 
 
Table 2: Adverse E vents Reported ≥ 20%  in Clinical Studies 
  
 
 
 
All Pa tients 
(n=911)  
All G rades 
Grades  3/4   
 
 
Chronic 
Phase 
(n=488)  
 
Grades 3 /4  
 
 
Accelerate 
d Pha se 
(n=186)  
 
Grades 
3/4  
 
Myel oid 
Blast 
Phase 
(n=132)  
 
Grades 
3/4 Lymph oid 
Blast Ph ase 
and 
Ph+ ALL 
(n=105)  
 
Grades 3 /4 
      
Preferred Term Percen t (%) of Pa tients 
Fluid Retent ion 50 9 6 6 23 9 
Super ficial Ede ma 36 1 0 2 3 2 
Pleural Effusi on 22 5 3 3 14 8 
Diarrhea 49 5 3 10 8 6 
Headache 40 2 2 2 4 6 
Hemorrhage 40 10 3 18 23 17 
Musculoskelet al Pain 39 4 2 3 6 13 
Pyrexia 39 5 1 5 13 9 
Fatigue 39 3 2 4 4 8 
Skin Rasha 35 1 1 1 1 4 
Nausea  34 1 <1 0 5 2 
Dyspnea 32 6 5 7 11 9 
Cough 28 <1 <1 1 1 0 
Infection (including 
bacter ial, viral, fungal, 
non-specif ied)  
 
34  
 
7  
 
4  
 
8  
 
15  
 
13 
Infectio n/Inflamm at 
ion  
26  
1  
1  
1  
5  
1 
Abdom inal Pain 25 2 1 2 4 6 
Pain 26 2 <1 1 5 4 
Vom iting 22 1 1 2 2 2 
Febrile Neutropenia 9 8 2 11 17 20 
Proprietary Information of MD Anderson
5   MDACC# 2010- 0794  
  Version Date: 6.13.17  
 Myelosuppre ssion w as commonly reported in all pa tient popul ations. The frequency of Grade 3 or 4 
neutropen ia, thrombocy topenia, and anem ia was higher in patients with advanced  CML or Ph+ ALL than 
in chronic pha se CML. M yelosuppr ession w as reported in patients w ith nor mal baseline lab oratory values 
as well a s in pat ients with pre-existing laboratory abnor malities ( Table 3). 
 
In pat ients who exper ienced severe myelosuppr ession, re covery g enera lly occu rred following dos e 
interruption and/or reduction; perm anent discontinuation of treatment oc curred in 1% of  patients. Grade 3 
or 4 elevati ons of tr ansaminas es or bil irubin and Grade 3 or 4 hy poca lcemia and hypophospha temia 
were report ed in patients with all phas es of C ML but were re ported with an increased fre quency in patients 
with myel oid or lymphoid bla st CML and Ph+ ALL. E levations in transaminases or bi lirubin were u sually 
manag ed with do se reduction or inte rruption. Pat ients developing Grade 3 or 4 hypocalce mia during the  
course of dasatinib therapy often had recovery w ith oral calci um supplem entation. (Tab le 3). 
 
Table 3: CTC G rades 3/4 Labor atory Ab normalities in Clinical Stu dies 
 
 
 
Chronic 
Phase 
  (n=488)    
 
 
Accelerated 
Phase 
(n=186)    
 
 
Myel oid 
Blast Phase  
(n=132)   Lymp hoid 
Blast Ph ase 
and 
Ph+ ALL 
(n=105)   
Percent (%) of Patients 
Hemato logy Parame ters 
Neutropenia 49 74 83 81 
Thrombocytopen ia 48 83 82 83 
Anemia 18 70 70 51 
Biochemistry P arameters 
Hypophospha temia 11 13 23 21 
Hypocalcem ia 2 9 20 15 
Elevated SGPT (ALT) 1 4 7 11 
Elevated SGO T (AST) 1 2 5 8 
Elevated Bilirubin <1 1 5 8 
Elevated C reatinine 0 2 1 1 
CTC   grades :   neutropen ia   (G rade   3   ≥0.5–1.0   ×   109/L,   Grade   4   <0.5   ×   109/L); 
thrombocytopen ia (Grade 3 ≥10–50 × 109/L, Grade 4 <10 × 109/L); anemia (hemoglobin 
≥65–80 g /L, Grade 4 <65 g /L); elevat ed creatinine (G rade 3 >3–6 × upper limit normal 
range (ULN ), Grade 4 >6 × ULN ); elevat ed bilirubin (G rade 3 >3–10  × ULN, G rade 4 >10 
×  ULN );  elevat ed  S GOT  or  SGP T  (Grade  3  >5– 20  ×  ULN,  G rade 4  >20  ×  UL N); 
hypocalce mia (G rade 3 <7.0–6.0 mg /dL, Grade 4 <6.0 mg /dL);  hypophospha temia (Grade 3 
<2.0–1.0 mg/dL, Grade 4  <1.0 mg/dL).  
 
Myelosu ppression  
Treatment with da satinib B  is associated with sever e (NCI CTC Grade 3 or 4) thrombocytopenia , 
neutropen ia, and anem ia. Their  occurrence is more frequent in patients with advanced  CML or Ph+ ALL 
than in chronic phase CM L. Com plete blood counts should be perform ed weekly for the fir st 2 m onths 
and then m onthly thereafter, or as clinically indicated. Myelo suppression w as genera lly reversib le and 
usual ly managed by withholding dasatinib temporarily or dose  reduct ion (SPRYCEL ® (da satinib) Table ts 
Prescribing Information.  B ristol-Myers Squibb Com pany  P, NJ. June 2006.).  
 
Proprietary Information of MD Anderson
6   MDACC# 2010- 0794  
  Version Date: 6.13.17  
 In addit ion to causing thrombocy topen ia in hum an subjects, dasa tinib caused platelet dysfunct ion in vitro. 
Severe CNS hemorrhag es, inclu ding fatalitie s, occur red in 1% of pati ents receiving dasatinib. Severe 
gastro intest inal hem orrhage occu rred in 7% of patients and g enerally required treatment interruptions an d 
transfusio ns. Other cases of severe hemorrha ge occurred in 4% of pat ients. Most bleeding ev ents wer e 
associated w ith severe thrombocytopeni a. 
 
Patients were excluded from par ticipation in  dasatinib clinical studies if th ey took m edications that inhibit 
platelet function or anticoag ulants. Caution shoul d be exercised if pati ents are requi red to take 
medications that inhibit platelet function o r anticoagulants. 
 
Fluid Ret ention 
 
Dasatinib is associated with fluid retention, w hich was severe in 9% of pat ients, including pleural and 
perica rdial effusion reported in 5% and 1% of pati ents, respectively. Severe ascites and generaliz ed 
edema were each reported in 1%. Severe pulm onary edema w as repor ted in 1% of patients. Patients who 
develop symptoms suggestive of pleural ef fusion such as dyspnea or dry cough shou ld be evalua ted by 
chest X- ray. Severe p leural effusion m ay require thorac entesis and oxyg en ther apy. Fluid retentio n 
events were typically managed by suppor tive ca re measures that inclu de diuretics or short courses of 
steroids SPRYCEL® (da satinib) Tablets Prescribing Information. Bris tol-Myers Squibb Company P, NJ. 
June 2006. 
 
QT Prol
ongation  
 
In vitro data suggest that dasatin ib has the pot ential to prolong cardiac v entricular repolarization (Q T 
interval). In single-arm cl inical studi es in patients with leukemia treated with dasatinib, the m ean QTc 
interval chan ges from baseline using Fridericia ’s method (QTcF) were 3–6 m sec; the upper 95% 
confidence intervals for all m ean chan ges from  base line were <8 m sec. Nine pa tients had QT c 
prolongation repor ted as an  adverse ev ent. Th ree patients (<1%) experienced  a QT cF >500 m sec. 
 
Dasatinib should be administered with c aution to patients who have or m ay develop prolongation of QTc . 
These include pat ients with hypokalem ia or hypomag nesemia, patients with cong enital long Q T 
syndrom e, pati ents taking anti-arrhythmic medicines or o ther m edicinal products th at lead to QT 
prolongation, and cum ulative high-dose anthracycline therapy. Hy pokalem ia or hypomag nesemia shoul d 
be corrected pr ior to dasatinib administration (SPRYCEL® (dasatinib) Tablets Prescribing Information. 
Bristol-Myer s Squibb Company P, NJ. June 2006). 
 
Phase I exper ience in Sol id Tumors  
 
In a Phase I  study (CA 180003) conduct ed by B ristol Myer s Squibb ( BMS), dasatinib w as ad ministered on 
a BID schedu le to 42 subjects with refractory solid tumor. To da te, doses up to 160 mg BID on a 5-da y 
on/2-day off schedule have been administered. A dose of 120 mg BID continuous dai ly sched ule is 
currently under investigation. 
 
No severe clin ical toxicity has be en encounte red. Gastrointestinal sym ptoms were repor ted in most 
subject s, fatigue w as reported in 17 subjects (40%) a nd rash in 10 subjects (24%). Edema, lethargy and 
head ache were uncommon, and appear to be dose-related. Grade 3 asymptomatic hy poca lcemia was 
consi dered dose- limiting in one subject, G rade 2 rash was considered dose- limiting in two o ther subject s, 
and G rade 2 na usea and vom iting (with dysa rthria, lighthea dedness and lethargy in a 49 kg subj ect taking 
concu rrent d iazepam ) was consider ed dose- limiting in one subject. 
 
In another Phase I study (CA180021), dasa tinib was administered on a QD schedule to 24 sub jects at 
doses up to 180 mg. Pleur al effusions were observed in three subjects at the 180 mg dose level (one with 
pneum onia and two with malig nant effusion). A dose of 250 mg QD is currently under considerati on. 
Hypocalcem ia, GI  symptom s and s kin rash  have been  mild and infr equent. 
 
To da te, the safety profile in solid tumor subjects has been  similar to that in CP C ML subjects with th e 
excep tion of severe myelosuppr ession, whi ch has not b een observ ed in solid tumor subjects and i s 
consi dered related to ef ficacy against the leukemia as noted abov e, and severe bleeding which is secon dary 
Proprietary Information of MD Anderson
7   MDACC# 2010- 0794  
  Version Date: 6.13.17  
 to thrombocytopenia in most instances. 
 
2.3 Tis sue Acq uisition Method Fine Nee dle As piration of Breast Tissue and  Bioma rker Evaluation  
 
Interm ediate biomarker s of cance r are phenotypic, gen otypic, a nd m olecu lar changes that  occur during 
carcinog enesis. Currently there are no validated surrogate endpo int biomarkers for brea st cancer in the 
conte xt of chemoprevention trials with invasive cance r as the definitiv e end p oints; therefo re the 
identifi cation and val idation of i ntermediate biomarker s as surrogate end points for subsequent larg e 
clinic al chemoprev ention tr ials for breast cancer is very im porta nt. In our cu rrent proposal, breast t issue 
and se rum biomark er modula tion that wi ll reflect dasatinib activity will b e evaluat ed. Thes e will include, 
in breast tis sue, cytologic chan ges, m arker s of proliferati on, apoptosi s and  chan ges in pro teomic profiling ; 
in serum marker s of IGF pathw ay (IGFB P1, IGFBP-3, IG F-I). 
 
Studies using periareolar fine nee dle aspiration (FNA) of th e breast a s a tissue acquisit ion method in 
phase I  and II breast  cancer prev ention trials have been pioneer ed and successfully completed by Fabian 
et. al  (11) and is now consider ed to be  an acceptable method, in ear ly phase b reast cance r prevention 
studies (12)  We have succ essfully used and ar e currently using th is method in our prev ention trials (13), 
(14). In our exper ience, this met hod is highly accep table from the patient point of v iew, as a ll of our 
patients retu rned fo r their second F NAs and ha ve not com plained about th e procedure. There fore, we wil l 
use this method in our p roposal. 
 
Conclusion and C linical Relevance:  
 
Phase III breast  cancer prevention t rials requi re large number s of patients, a long duration of follow-up, 
and a re costly. A s an alternativ e strategy, short- term chemoprev ention tria ls uti lizing surrogat e marker s of 
drug activ ity may allow for a small sam ple si ze and bri ef dura tion of exposu re to assess the efficacy  of 
potenti al chemopreventive agents. The re is an immediate need to evaluat e agents that can  reduce the risk 
of ER  negativ e breast cancer developm ent. Finally, pot ential preventive agents should hav e a favorable 
safety profile. Taken all these and  the preclin ical information prov ided abo ve, we  are proposing a short- 
term phase II study ev aluating t he e ffects of dasa tinib in women who are at increa sed r isk to develop a 
second  primary breast cancer. Our aim is to un derstand the pathw ay that is involved in ER  negativ e breast 
cancer developm ent and pr ogression so that further stu dies w ith agents that target the s rc pathway 
(exam ple p 70S6K inhibitors) could b e undertaken th at will ultimate ly lead to the development of 
prosp ective pha se III studies targeting ER negativ e breast cancer prevention. 
 
 
3. SUMMARY OF S TUDY PLAN  
 
This is a phase II, prospec tive biomark er modulation study in wom en with a p rior his tory of ER  negativ e 
breast cancer who have currently no active disease and have complet ed all ad juvant therapy. Wom en wi th 
a previous history of breast cancer hav e a 0.5-0.8%/year r isk to de velop a c ontralateral primary breast 
cancer ( 15), (16) an d  hence represent a high risk study cohort.  S ixty six eval uable patients after signing 
inform ed conse nt will underg o bas eline periareolar FNA of th e breast and blood coll ection for th e 
analysis of the proposed  markers.  Participan ts will take no drug, or th e study drug dasa tinib at a dose of 
40mg or 80mg daily for 3 months (+/- 7 day s) and  at the end of the 3 months (+/- 7 day s) wi ll undergo a 
repeat FNA an d blood collection for the same mark er analy ses. The study will be under taken at th e 
Universi ty of Tex as, M.D.  Anderson C ancer Center and Duk e Uni versity . Patients will return to clinic at 
month 1 for  evalua tion and agai n at month 3 and wi ll be followed-up w ith a phone ca ll at month 2. 
Assuming a scree ning rate of app roximately 20 parti cipants pe r month and a  conservatively es timated 
accrual rate of 2 pat ients per months we wi ll be ab le to complete accrual in 30 months. 
Proprietary Information of MD Anderson
8   MDACC# 2010- 0794  
  Version Date: 6.13.17  
  
 
4. PARTICIPANT SE LECTION  
 
4.1 Inclusion Cr iteria 
 
1. Histological conf irmation of ER negative (defined as less than 10%) breast carcinom a, sta ge I, II, 
or III 
 
2. Com pleted a ll adjuvant therapy including ( if indica ted) endoc rine, trastuzumab, rad iation therapy. 
 
3. At le ast 18 y ears of ag e. 
 
4. Female: 
 
A female is elig ible to enter and partic ipate in the s tudy if she is of: 
 
a. Non-ch ildbear ing p otential (i.e., wom en wi th func tioning ovar ies who hav e a 
current docu mented tubal ligati on, hysterectomy alone, hysterectomy and 
bilateral salpingo -oophorectomy, bilateral salpingo- oophorectomy alone , or 
women who are post-menopausal ); or 
 
b. Childbearing p otential (i .e., wom en wi th functioning ovar ies and no d ocumented impairm ent 
of oviductal o r uterine function that would cause sterility.  Th is categ ory includes women 
with oligomenorrhoe a (severe), women who are pe rimenopausa l, and  young wom en who 
have beg un to menstr uate), h as a negativ e urine or se rum pregnancy test at screening, and 
agrees to one of the fol lowing wher e considered acceptable to the local IRB/IEC: 
 
• Double-barr ier contraception (con dom with sp ermicidal j elly, foam  suppository , or 
film; diap hragm with sperm icide; or male condom and d iaphragm). 
 
• Abstinenc e from sexual  inter course from 2 w eeks prior to  administration of 
the investigat ional product, thr oughout the active study t reatment period. 
 
• Male partner who is sterile prior to th e femal e subject's entry into the study and is the 
sole sexu al part ner for that female subject. 
 
• Any intrauterine devic e (IUD ). 
 
• Barrier methods including diaph ragm or condom w ith a sp ermicide. 
 
5. Able t o swallow and retain oral m edication. 
 
6. ECOG (Eas tern Cooperativ e Onco logy G roup) pe rformance st atus 0  to 2. 
 
7. Provide wr itten informed consen t. 
 
8. Adequat e bon e marrow function 
• Hemoglobin ≥  9 gm /dL. 
 
• Absolu te granulocy te coun t ≥ 1,500/mm3 (1.5 x 109/L). 
 
• Platelets ≥ 75,000/mm3 (100 x 109/L). 
 
9. Serum  crea tinine < 1.4 mg/dL or calcula ted creatinine clea rance (CrCl) ≥ 30 m L/min 
 
10. Total bili rubin ≤ 1.5 times the uppe r lim it of th e refere nce r ange 
 
11. Aspar tate and  alanine transaminase (AST o r ALT) ≤ 2 times the uppe r lim it of the reference range 
 
12.  Patients must have  a base line ECG with QTc F within the nor mal range within 28 d ays prior to 
registration. 
 
13.  Norm al mammogram of unaff ected b reast within 12 months pr ior to study entry. 
Proprietary Information of MD Anderson
9    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 4.2 Excl usion Cr iteria 
 
 
1. Unw illingness to undergo RPF NA. 
 
2. Contra indication to RPFNA inc luding br east im plant(s), b ilateral r adiation, anticoagulation 
(excluding those on 81mg aspirin) . 
 
3. Concur rent medical condi tion that wou ld increase drug toxicity: Pleural or pericardial effusion, 
coag ulation or plate let function disorder, ongoing or recent (less than 3 months gastroin testinal 
bleed ing) 
 
4. Uncont rolled angina, cong estive heart fai lure, MI  (within last 6 months), cong enital long Q T 
syndrome, histo ry of clinical ly signifi cant v entricular ar rhythmia, prolonged QTcF interval  on 
pre- en try EKG (g reater than normal range) 
 
5. H
ypokalem ia or hypomagnesem ia if it cannot be cor rected 
 
6. Is a pregnant or lactating femal e. 
 
7. Has ev idence of recurrent or met astatic (Stage IV) breast cance r. 
 
8. Is considered m edically unfit for the study by the investigator as a result of the m edical 
interview, physi cal exam, or screening investigations. 
 
9. Has a known imm ediate or delay ed hyper sensitivity reaction o r idiosyncr asy to dasatinib 
 
10. Has received treatm ent with any  investigational drug i n the previous 4 w eeks. 
 
11. Has received c hemotherapy, immunotherapy, biolog ic therapy or endocrine therapy w ithin the p ast 
12 w eeks. 
 
12. Is cu
rrently receiving oral steroid treatment (inhaled steroids a re perm itted) 
 
13. Oral estrogen, p rogesterone, testosterone therapy within last 3 months. 
 
14. Concomitant Medications:   Drugs that are considered category D (Consider therapy modification) 
and X (Avoid combination) using the Lexicomp database are prohibited. Concomitant drugs that fall 
into categories A (No known interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
4.3 Inclusion of Women and Minoriti es 
 
Since  our research topic, br east cancer, is relevant to women, all o f our  participants will be wo men of al l 
races and  ethnic groups. Mal e breast cancer is seen very rarely, therefo re, we will not include mal e 
partic ipants. The research topic to be studied, b reast cancer, main ly effect s the adult population and i s 
not relevant t o children. Therefore, we will exclud e individuals who a re und er 18 y ears o f age. Our 
resear ch propos al will s tudy wom en who are at increased  risk to devel op a second p rimary breast 
cancer. 
 
4.4 Recruit ment and Ret ention Plan  
 
Pre-initiation Recruitm ent 
During the pre- initiation re cruitment pha se, physicians w ithin or outsid e the Instit ution working w ith 
patient popula tions that include po tential par ticipants will be  contac ted, the speci fic inc lusion/exclusion 
Proprietary Information of MD Anderson
10    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 criteria reported, and the import ance of accruing  parti cipants who a re likely to b e com pliant  and 
retainable wi ll be em phasi zed. Contact wi th outside referring physic ians will mainly take place by  e- 
mail, and Newsletters, or by face-to-face m eeting  during outre ach sem inars, which is org anized by the M. 
D. Anderso n Physician R eferral Serv ice and the Ph ysicians Netw ork. Information about the study and 
eligibil ity criter ia wil l be pl aced o n our website. Inv estigators at each s ite will p resent the study to 
potenti al referring physicia ns wi thin the Institu tion to expla in the goa ls for the study, describe the 
proto col, discuss enro llment procedures, and  provide contact informat ion. Beside accrual from UT M.D. 
Anderson C ancer Center, a maj or sour ce for minor ity referral for the study will be referrals from Lyndon 
B. Johnson (LBJ) H ospital, Houston, which primarily serves the minor ity and underserved popula tion 
and is sta ffed by Facu lty members from  UT M.D. Anderson Cance r Cen ter. A re cent search of the LB J 
Hospi tal database indi cated that in the la st 5 years, 42% of the pa tients w ho were seen at LBJ Ho spital 
were African Americ an and  28% we re of Hispan ic origin. W e believ e that LBJ Ho spital will serv e as an 
ideal referr al sour ce for mi nority accrual for our proposed s tudy. 
 
UT M.D. Anderson Can cer Center recently open ed a new cen ter “Center for Re search on M inority 
Health”. This center provid es an o pportunity for this trial to be publicized. Sp ecifically, the PI  will hav e 
an initial m eeting  with the Director of that Center, D r. Jones, and bri ef him and hi s staff abo ut the study 
and prov ide th em with an  eligibility  summary card. Ou r study coordinator will then do bi-w eekly 
follow- ups with t hat team to evaluat e potential eligible partici pants. Thes e can be done vi a e-mail or 
telephon e. 
 
Other sources for minority recruitment will include working together with community  and local 
organizations such as: Sisters' Network, Inc., One Hundred B lack Women, Na tional Association for the 
Advancement of C olored People, Inc., Top L adies of Distinction, Inc. and th e African Methodi st 
Episc opal Church. W e conservatively es timate that 10-15 % o f the study participants wi ll belong to the 
minority  population. B esides these promising 5 comm unity  partnering programs, our p rogram engages 
in a varie ty outreach prog rams, such  as local chur ches,  local shop ping centers.  Br ochures about the 
study w ill be taken to any ev ents or functions the abo ve mentioned  organizations are doing. 
 
Activ e Recruitment Phase 
We hav e a very well developed web b ased communica tion syst em at UT MD Anderson Cente r whi ch 
will ass ist us in posting newsl etters and advertising th e trial on our we bsite for the publi c as w ell as for 
local and na tionwide oncologists. 
 
MD Ander son Can cer Center serv es as a resource through outre ach programs such as MD Anderson 
Information Line, The Anderson Network, and th e Information Serv ice. Through thes e programs we w ill 
alert the community  and health ca re professiona ls about th is study. W e also have perio dic publications 
addressing various hea lth related issues, including prev ention o f cancer. “C ancerWise” for example is 
monthly publicat ion wi th reports on adv ances in c ancer prev ention, treatment a nd research. F inally, loca l 
representatives of the A merican C ancer Society and the Susan G. Kom en Bre ast Cancer Foun dation, w ith 
which we hav e already  close rela tionships, wi ll help us  advertising the study. The  outreach programs will 
help u s accr uing m inori ties as well, such a s MD  Anderson Informat ion Li ne, The Anderson Network , and 
CancerWise Comm unity S peakers Bureau.  In addit ion, to increase minority accrual and incre ase 
aware ness about t his study w ill be wor king together with som e of the local org anizations such a s: Siste rs' 
Network, Inc., One Hundred B lack Women, National A ssociat ion for the Adv ancement of co lored People, 
Inc., Top L adies of Distinction, Inc. African Methodist Ep iscopal Church. 
 
Reten tion Plan 
In our study, par ticipants will return to clin ic in 1 and 3 months; m onth 3 i s usually the fol low-up interv al 
for our adjuv ant patients during their initial 2 y ears after complet ing adjuvant therapy . Patie nts beyond 
these 2 y ears usually are seen every 6 months, there fore, fo r these patients there may be 2 extra visit s 
(month 1 and 3 ) which would be sponso red by the study. 
 
We wi ll also striv e to retain par ticipants by offering well-trained, friendly staff, consis tent monitoring of 
Proprietary Information of MD Anderson
11    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 recruitment and adherence; and sp ecific efforts early in the study to enthusiastically engage compliant 
partic ipants in the tria l. 
 
5. AGENT AD MIN ISTRATION  
 
Interv ention wi ll be adm inistered o n an ou tpatient ba sis.  Rep orted advers e events and po tential risks are 
described i n section 6.2. 
 
5.1 Dose Re gimen and  Dose Groups  
 
Participants will r eceive da satinib at 40mg , or 80mg o nce a day or no d rug. Dasatinib wi ll be taken for 3 
months (+/- 7 days). I f a dose is missed by  more than 12 hour s, the dos e should be om itted.  Table ts 
should not be c rushed and be swallowed as a who le. Dasatin ib can be  taken with o r without a meal. 
 
5.2 Study Agent Adm inistration  
 
• The part icipant wi ll self- administer dasat inib by m outh.  
 
5.3 Run- in Procedures 
N/A 
 
 
5.4 Prohibited T herapies 
Drugs that are considered category D (Consider therapy modification) and X (Avoid combination) using 
the Lexicomp database are prohibited. Concomitant drugs that fall into categories A (No known 
interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
5.5 Restricted Therapies 
Drugs that are considered category D (Consider therapy modification) and X (Avoid combination) using 
the Lexicomp database are prohibited. Concomitant drugs that fall into categories A (No known 
interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
 
5.6 Concomit ant Med ications 
 
• No othe r investigational therapy will be given to pat ients. 
 
• The use of an ticancer age nts (other than hormonal ther apy) or radiation therapy i s not a llowed 
(an exception would be t he use of meg estrol acetate for the t reatment of anorexia ). 
 
• Patients enrolled in the Phase I portion  of the trial may not r eceive GC SF or GMC SF during  
cycle 1 o f therapy. The use o f hematolog ic grow th factors for the treatm ent of ane mia is allowed 
at any time during protocol  therapy. Patients enroll ed in the P hase II portion of t he trial or those 
who have comple ted >1 cycle of therapy in the phase I por tion of the trial m ay receiv e growth 
factor support as per ASCO g uidelines. 
 
• Drugs that are considered category D (Consider therapy modification) and X (Avoid 
combination) using the Lexicomp database are prohibited. Concomitant drugs that fall into 
categories A (No known interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
5.7 Dose Modifi cation 
 
For g rade 1  toxicity or less, no dose m odifi cations will be m ade. For g rade 2 or greater toxic ity probably, 
possibly, or def initely related to d asatinib, dasatinib will be held unt il recovery at least to grade 1 and 
patient will re-start at  one lower dose lev el if applicable (80 mg to 40). F or grade 3 or 4 toxicity the study 
Proprietary Information of MD Anderson
12    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 drug w ill be d iscontinued. 
 
5.8 Adherence/Comp liance 
 
• Participants who  are randomiz ed to the treatm ent group will be eval uable if they r eceived 
at least 75% o f their assigned d asatinib dose.  No im putation will be performed on 
missing data 
 
• The fo llowing 2 methods will be u sed to monitor each partic ipant’s agent compliance: 
1) Participan ts will be giv en a pill diary  and instructed to initial it each time a 
dose is taken 
2) At the end o f the treatment period, the ac tual qua ntity of un used drug will 
be co mpared to the an ticipated amount of unu sed d rug and particip ant pill 
diary . 
 
6. PHA RMACEUT ICAL IN FOR MATION 
 
6.1 Study Ag ent 
 
Dasatinib tablets are whit e to off-w hite, biconvex, fi lm-coated  tablets containing dasat inib, with the 
following inactive ingredients: lacto se monohy drate, microcrystall ine cellulose, cros carmellose sodium, 
hydroxypropyl cellulose, and mag nesium  stearate. The ta blet coating consis ts of hypromel lose, titanium 
dioxide, and polyethy lene gly col. 
 
Preclinical Tox icology 
 
Single or repeated oral adm inistration of dasatin ib principally affected the g astro-intes tinal (GI) tract, 
including the liver, the hematopoieti c, and lymphoid systems in rats and monkey s. Other prominent 
effects after s ingle oral adm inistration of dasat inib included renal and cardiac toxicity in rats at lethal 
doses,  and cu taneous hemorrhage in monkey s. Dasatinib can a lso affect the i mmune syst em and bone 
turnover. 
 
Dasatinib in vitro activ ity in the HERG/IKr and Purkinje- fiber  assays indi cated a m oderate l iability for 
prolongation of cardiac ventricular repolarization (QT interval) in the clinic. However, there were no 
dasatinib -related chan ges observed in electrocardiograms, nerv ous syst em function, re spirations an d 
heart ra te, blood pressure, or ar terial ox ygen  satur ation in single-dose, 10-day, or 1-month oral toxicity 
studies in m onkeys. 
 
Dasatinib was found to exhibit a profi le of broad- spectrum platel et inhibition be st typified by anti-platele t 
agents such as the GPIIb/IIIa an tagonis ts, integrelin and abciximab. 
 
Finally, modulatio n of S RC k inase ac tivity could a lso affect osteoclast m orpholo gy and funct ion and bo ne 
remodeling. This effect could po tentially result in an increase in bone m ineral densi ty and a phenoty pe 
analo gous to oste opetrosis(15). 
 
Clinical Pharmacokinet ics 
 
The pharm acokinet ics of d asatin ib have been evaluat ed in 229 healthy subjects and in 137 pat ients with 
leukemia. 
 
Absorp tion 
 
Maxi mum plasma concen trations (C max) of dasatinib are observ ed between 0.5 and 6 hou rs (T max) 
following oral administration. d asatinib exhibits dose propor tional incr eases in AUC and linear 
elimination characterist ics over the dose range of 15 mg to 240 mg/day. The overa ll mean term inal half- 
life of dasatinib i s 3–5 hours(14 ). 
 
Data from  a study of 54 h ealthy subjects administered a s ingle, 100-mg dose of Dasatinib 30 minu tes 
Proprietary Information of MD Anderson
13    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 following consu mption of a high- fat meal resulted in a 14% increase in the mean AUC of dasatinib. Th e 
observ ed food effec ts were not c linical ly relevant. 
 
Distribution 
 
In pat ients, dasa tinib has an appa rent volume of distr ibution of 2505 L, suggesting  that the drug is 
extensively d istributed in the extrav ascular space. Binding of dasat inib and its  active metabolite to hum an 
plasma prote ins in vitro was approximately 96% and 93 %, respectively, w ith no concentratio n 
depend ence over the range of 100– 500 ng/m L(14 ). 
 
Metabolism 
 
Dasatinib is extensively met abolized in humans, primarily by the cytochrome P450 enzyme 3A4 (see 
section 7.6). CY P3A4 was the primary enzyme respons ible for the f ormation of the active metabol ite. 
Flavin-contain ing monooxyg enase 3 (FMO-3) and uridine dipho sphate-g lucuronosy ltransferase (UGT) 
enzymes are  also involved  in  the formation  of  dasatinib  metabol ites. In human liver microsom es, 
dasatinib wa s a w eak time-depend ent inhibitor of CYP3A4. 
 
The exposu re of the active metabolit e, which is equip otent to dasatinib, represents approximate ly 5% of 
the d asatinib AUC. Th is indicates th at the active met abolite of dasat inib is unlikely to play a major rol e 
in the observed pharm acology of the d rug.  dasatinib also had several ot her inactive oxidativ e metabol ites. 
 
Elimination 
Elimination is primar ily via the fe ces. Following a s ingle oral dose of [14C]-labeled  dasatinib, 
approximately 4% and 85% of the administered radioactivity was recovered in the uri ne and feces, 
respectively, w ithin 10 day s. Unchang ed dasatinib accounted for 0.1% and 19% of the admin istere d dose in 
urine and feces, respec tively, with the remainder of the dose b eing m etabolites(14). 
 
 
6.2 Rationale for Dose Selection: 
 
Since  our aim in this pilot biomark er prev ention study i s to identi fy the m inimal dose required to 
induc e bio mark er modulation by dasa tinib i n high risk breast epithelium and not to identify the 
maximum tolerated dose for antitumor eff icacy, w e will not pe rform a traditional phase I dose 
escala tion study that is utilized in metas tatic pha se I studies (as MTD for an ticancer treatment ha s 
already been de fined). Pre vious studie s have sho wn con siderable toxicity with 100 mg of dasatinib, 
therefore, in ou r pilot biomark er modulation s tudy, we will rando mly assign patients to 0,40, or 80 mg 
daily dasat inib and pe rform ongoing evaluation of toxicity (pl ease see toxicity evaluati on section (12). 
 
6.3 Availabili ty 
 
Dasatinib wi ll be requested from  BMS. As an al ternativ e plan, da satinib wi ll be purchase d using other 
fundi ng mechan isms. 
 
6.4 Agent Ac countabili ty 
 
The PI, or a respons ible party designated by the investigator, wi ll maintain a car eful record of  receipt, 
disposi tion, and re turn of all study drugs on t he Inv estigational Ag ent Account ability Record. Al l study 
drug supplie s will be kept in a locked, lim ited a ccess area. The study drug will not be use d outside the 
conte xt of the p rotocol. Under no ci rcumstan ces will the investigator or other site personnel su pply study 
drug to o ther patients, or clinics,  or al low supplies to b e used  other than directed by this p rotocol. Study 
agent will not be t ransferred from  one pati ent to another, o r from one p rotocol to another. A ll other 
transfers ( i.e. pat ient or PI  mov es) must be ap proved in adv an ce by  the st udy PIs. 
 
The investigator will maintain records docu menting th e receipt, u se, loss or other disposi tion of the 
investigational product, including bat ch or code numbe rs, and account fo r it’s disposition on a subject-by- 
subject basis, including specific dat es and qua ntities. The so urce docu ment, docum enting the su bject ’s 
Proprietary Information of MD Anderson
14    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 partic ipation in th is rando mized clinical trial, m ust be docum ented in th e medical and re search records. 
Destruction will be docum ented in accordance wi th institutional SO Ps. 
 
6.5 Packa ging a nd Labels  
 
Dasatinib wi ll be packaged in bott les as follows: 
• Dasatinib 20 mg film- coated table ts, 30 ta bs/bottle 
Each b ottle will be labeled in an open label.  L abels will contain, at a minimum , the following 
informat ion: product nam e, tablet st rength, batch num ber, directions for use, storage con ditions, and 
appropriat e caution sta tements. 
 
Stora ge-Handl ing and Disposal Dasatinib tablets should be s tored in a secure area at 25⁰C 
(77⁰F ); excu rsions perm itted between 15 –30⁰C (59–86⁰F). 
 
Proce dures for pro per handling and disposal of ant icancer d rugs should be con sidered. There is no g eneral 
agreement that all of the pr oced ures recommended in the g uidelines are necessa ry or app ropriate. 
 
Dasatinib tablets consist of a core tablet ( containing the active drug substance), surrounded by a fi lm 
coating to  prevent expo sure of pharm acy and clinical personnel to the ac tive drug substanc e. However, if 
tablets are crushed or br oken, pharm acy and cl inical personnel should w ear disposab le chem otherapy 
gloves. Person nel who are pregnant should avoid exposure to crushed and/o r broken ta blets 
 
6.7 Registration  
 
Participating institutions wi ll register all partic ipants per their IRB ins titutional pol icy.  In addi tion, 
partic ipants will be registered and randomiz ed at  MDACC.  Reg istration wi ll be completed in th e 
MDACC O ffice of Research Adm inistration computer  system COR e (Clinical On cology 
Research ).  COR e will assign the o verall p rotocol acce ssion number.   The randomization prog ram 
based on t his method wil l developed by the De partm ent of B iostatistics, and the p rogram w ill be 
available via an intr anet web site of MDACC. 
 
6.8 Agent Ad ministration 
 
Upon randomizat ion o ne month supply of study drug w ill be dispensed  to the patients randomized to the 
treatm ent arms. Additional bottle s will be dispensed at 1 month cli nic vi sits, a s necessary , to e nsure that 
the sub ject has sufficie nt study drug to la st until the ne xt planned clinic vis it. Follow-up schedu le will be 
taken in to consideration when drug is dispensed a nd those wi th the modif ied vis it sched ule will be 
provided an adequa te supply to last until ne xt vis it. 
 
During stu dy partic ipation, subject s will be ask ed to: self- administer the study medic ation; av oid certain 
medications/supplements and complete dai ly logs to rec ord s tudy agent i ntake, conco mitant 
medications, and A Es. Su bjects are expecte d to: maintain ≥75% co mpliance  with study ag ent intake; 
comply with dietary, m edication and supplem ent restrictions; and com plete the daily log. 
 
6.9 Destruction of Dasa tinib 
 
At the completion o f investigation, all unu sed study agent wi ll be destroyed according to 
institutiona l guidelines. 
 
7. CLINICAL EVALUATION S AND PROCE DUR ES 
 
7.1 Schedu le of Events 
Please refer to Table 1 that lists baseline testing/pre-study evaluatio n, agent administration, study 
assessments, procedures and cas e report form s. 
Proprietary Information of MD Anderson
15    MDACC# 2010- 0794  
  Version Date: 6.13.17  
  
7.2 Base line Testing/Pre-study Eva luation 
 
7.2.1 If indiv idual  is eligible as outlined in section 4.1, she w ill sign con sent and she will 
be assig ned a participant i dentification number at th e time of en rollment and  the 
following proce dures wi ll be under taken: 
 
7.2.2 Data col lection wi ll include: m edical history, demogra phic information including 
race, ag e, hei ght, we ight, cancer family history, reproductiv e history (age at 
menarche, ag e at fi rst preg nanc y, outcome of each p regnancy , lactation and durat ion 
of each ep isode of lactation, histo ry of prev ious benig n bre ast disease (age at each 
breast biopsy and his tologies identi fied in each bre ast biopsy), horm onal medication 
use (ag e at fir st use and du ration o f use of oral contraceptives, hormone re placement 
or fertility drugs),and usual w eekly alcohol c onsumption.  
 
7.2.3 General physi cal exam, incl uding a clinical breast examinat ion, if these exam s were 
not performed in the last 12 months.  If the physical ex am and a clinical breast exam  
were perf ormed wi thin the past12 months, do not nee d to repeat them  for baseline.  I f 
a brea st mass is found on init ial physical e xam, the participant will receive an 
appropria te evaluat ion, and w ill not participate in the study unt il the mass has b een 
definitively classifi ed as benign. 
 
7.2.4 Gynecology evaluation within the last 5 years (as suggested by patient’s gynecologist) .  
Participants with a prior hysterectomy alone, hysterectomy and bilateral salpingo -
oophorectomy, or bilateral salpingo -oophorectomy alone are exempt from this 
requirement. 
 
7.2.5 Bilateral or uni lateral mammogram w ithin 12 months prio r to registrat ion. 
 
7.2.6 Blood d raw f or CBC with d ifferential, platelet c ount, electrolyte, Magnesium, l iver 
pane l (LFT)  within 3 months p rior to randomizat ion, EKG ( within 1 month),  i f 
norm al (upper limit nor mal is sufficie nt for liver panel , creatinine), and if eligible, 
patient will pr oceed to 7.2.8 
 
7.2.7.  Urine pregnancy  test (if not alr eady  completed within 14 day s prior to randomization 
or start of study ag ent, order STAT for results to be a vailable p rior to drug 
administration) for wom en of  childbearing potential. 
 
7.2.8 Breast periareola r fine need le aspiration (FNA),( baseline) 
(If part icipant is on a spirin (except those who take 81 mg asp irin), non -steroid al anti-
inflammat ory drug s and  Vitamin E,  she w ill be instructed to dis continue these and 
return in 7-10 day s for the F NA) FNA procedur e is descr ibed in section 7.5.6. 
 
7.2.9 Blood d raw f or research biomarker s (Day 0) 
 
7.2.10  The part icipant wi ll be randomized to drug or no d rug and the ones that are 
randomized to da satinib will be p rovided with a drug k it with a 3 month supply , and  a 
pill diary  and w ill be instructed to return any unused d rugs. The participant wi ll start 
dasatinib within 7 day s. Conco mitant medications will be docum ented. 
 
7.2.11  A 3-m onth fol low-up (+/- 7 day s) will b e scheduled and particip ants will be instruct ed 
to call i f any  sym ptoms occu r. 
 
7.3 Evaluati ons Dur ing Stud y Int ervention  
Proprietary Information of MD Anderson
16    MDACC# 2010- 0794  
  Version Date: 6.13.17  
  
At month 1 and 2:  Study nurse will call t he participant to document and g rade the pre sence of  adverse 
events, compliance  and conco mitant medications. 
 
 
7.4 Evaluat ions at Co mpletion of Study  Intervention  
 
Month 3 c linic vis it will include: Vi tal signs, AE, concom itant medication, and rev iew of s tudy 
medication tak en and pill counts. Particip ants will return ag ent diary and unu sed study m edication. 
Blood sampling fo r repeat biomarker s studies, and breast FNA wi ll be performed (The study drug can be 
taken on the biop sy day). 
 
7.5 Metho ds fo r Clinical Pro cedures  
 
7.5.1 M edical history: Research sta ff will obtain da ta from  a pros pectively mai ntained re search 
database that all UT MDACC brea st cance r patients are entered in. 
 
7.5.2 K arnofsky p erforma nce s tatus: Th e Kar nofsky Performance Sca le Index al lows sub jects to 
be m onitored  for bas ic functional status and to monito r any functional impairm ent. Although no 
changes in func tional impairm ent are anticipated, w e plan to uti lize th is scale to ensure optimum 
funct ional statu s to partic ipate in this clin ical tria l. Thi s will be recorded in the par ticipant’s CRF. 
 
7.5.3 Study agen t intake lo g (pill diary): Participants will be provided with a Study Agent Intake log 
(pill diary) which they will be required to complete daily. The pill diary will require the subject to 
check that study agent has been taken. Monthly, subjects will be contacted by a member of the  research 
staff by phone for review of: i) pill diary, and; ii) use of concomitant medications; iii) Anticipated and 
unanticipated, grades of constitutional, dermatological, gastrointestinal (GI), metabolic and pain 
symptoms noted;  
 
7.5.4 Adverse Events (AEs): Adv erse Even ts (AEs): All AEs that are reported by the su bject, 
detected during a visit, physical e xamination, o r laboratory work-up w ill be recorded in the 
participant’s study rec ord and re corded on the CRF. A ll AEs that occ ur after  the inform ed con sent is 
signed w ill be recorded on the AE CRF whe ther or not related to study ag ent. The fo llowing 
informat ion will be captured for each A E: da te repor ted; verbatim term; Common Toxic ity Criteria 
(CTCAE Te rm v 4.0); onset and re solution date; severi ty grade;  attribution to study agent; whe ther or 
not th e event was reported as an SA E; action ta ken; whe ther or not the subject d r opp ed due to the 
AE; ou tcome; and comments; 
 
7.5.5 Fine Need le As piration: In order to evaluat e changes in biomarker s patients will undergo 
FNA at base line and  3 month afte r taking dasatinib. The procedure is as follow s: 
 
The sk in of the periareolar region (upper and lower outer quadrants) is cleansed with an alcohol pr ep 
pad infiltrated with 0.1m . of 1% Lido caine mixed 9:1 within 8.3 sod ium bica rbona te. We wi ll obtai n 
pre and post d asatinib treatment FNA from  breast tissue (only 1 breast; the sam e breast wi ll be used 
for the repeat FNA) from  the m ost dense area, mostly at 3 o’c lock posit ion and 9 o’c lock positio n, 4 
passes at each pos ition, 8 pa sses total.  A 25-g auge need le attached  to a 10 ml sy ringe in a syringe 
holder is used to pe rform the a spiration. Th e nee dle is inserted into the breast to a distance of 1 – 1 
½. Suction is applied by pulling  on the plung er of the syringe, and the needle is mov ed back  and 
forth r apidly in the sam e plane w ithin the most de nse breast tissue. Suct ion is maint ained u ntil so me 
material app ears in the cl ear plast ic need le hub  (this m ay require as many as 20 up and down 
motions of the needle with continuo us suct ion). When mate rial appea rs in the hub o f the ne edle, the 
syringe plunger is rele ased and the n eedle is withdrawn.  The materi al obtained by fine n eedle 
aspiration is rinsed into the CytoLyt fix ative solution ( methanol based). Th e procedure is repeated, 
using a disposab le needle and a sy ringe. Once ce lls are in CytoLy t, the c ells will be fixed and the 
Proprietary Information of MD Anderson
17    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 vial can be  left in ro om temperatur e until next step. The cel ls are spun down and an al iquot of the 
sedim ent is re-suspend in Pr eserv eCyt so lution and then thin- layered slides are prepared us ing the 
Thin Prep P rocessor.  Thin- layer slide is fixed with 9 5% a lcohol and stained w ith Papanicolaou and 
cellularity of this slide is evaluated.  We then re-suspend the cell s in the remaining sediment in 
Preserv eCyt so lution and p repare as thin-layer slides, fix them with 95% a lcohol and a ir-dry and 
store them at -80C for the proposed markers.  A pr eprinted l abel wi ll be attached to ide ntify all 
sample v ials. Manual pressure is held ov er the biopsy site between each needle pass and f or 10 
mi
nutes after the last pass; partic ipants w ill then be given i ce packs to put p ressure over the biopsy 
site for 20 minutes. 
 
7.5.6 Biomark ers to be assessed: 
 
Cytomo rpho logy: FNA Cy tomorpholo gy is a valid and m odifia ble risk biomar ker and re sponse 
indicator for ear ly prevention trials and has b een reported to be  present about 25 % (range 15-50%) 
of hig h risk indi viduals{Arun, #3399}, {F abian, 1998 #3400}.Cytomorphology and Ki-67 
expression ar e inde pendent var iables considered complementary (17).Cytomorphology w ill be 
assessed by a sing le expert b reast cytopathologi st who will assig n a categor ical assessment of 
nonproli ferative, hyperpl asia, borderline hyperpl asia with atypia, o r hyperplasi a with aty pia (18). 
The patho logist w ill be b linded as to the p re and post d asatinib samples. 
 
Cell proliferation by Ki-67: The expr ession of the human Ki-67 protein i s associated w ith cell 
proliferation, a s this pro tein is present dur ing all ac tive phase s of the ce ll cycl e (G1, S, G2 and 
mitosis), but i s absent from resting cells G0, making it an ex cellent mark er for determining the 
growth fraction of a giv en ce ll population (19). Ki-67 has shown r apid mod ulation in previous 
studi es, including 14-da y treatm ent with Tamoxifen. It has al so dem onstrated co rrelation with 
subsequent clinical response ( 20). R ecent  studi es (14), (21), hav e demon strated that Ki-67 
proliferation index is an established, val id,  re liable mark er of prolife ration and th at chan ges in Ki-67 
in FNA i s a valid IEB of che moprev ention eff icacy. Slides in wh ich m ore than 5 00 epithelial cells are 
visible by Papa nicolaou staining w ill be further proc essed for Ki-67. A fter de-stai ning, antigen 
retrieval will be perform ed wi th a 10 nM/l citrate buf fer (pH  6) in a B iocare (Wal nut Creek, CA, 
USA ) decl oaking chamber (DC 2002 ) for 2 m in at 120°C. Sl ides w ill be stained w ith a MIB-1 
monocl onal antibody (M 7240 Dako Cy tomation; Dako, Carpenteria, CA, USA ) at a 1:20 di lution 
using a Dako autostainer. Hyperplas tic cluster s will be pr efe rentially assessed, and the num ber of 
cells with unequiv ocal nuclea r staining out of a total of 500 cell s will be assessed. 
 
Apoptosi s by the Caspase-3 Met hod: From  Cell Signaling Technology (CST ) we will obta in the 
Apoptos is Marker: Sig nal Stain Cleav ed Casp ase-3 (Asp 175) IHC Detection K it. This is a “ready  to 
use” syst em designed to detect t he activation o f caspase-3 in hum an cell preps by 
immunohistochem istry with which we hav e extensive expe rience. 
 
Other markers : If samples perm it slides that are prepared using the T hin P rep technique f rom 
Cyty c will be us ed fo r immunohost ochemitry studi es using previously described antibod ies for 
EGFR, phosphory lated EG FR and bcl-2, p-Y418- Src, p -Y-118- Paxillin,  and markers identified in 
Aims 1 and 3 of th e grant (IGF-1, IGFBP1 and 3). 
 
Proteomic Prof iling: Marker s of proliferati on and apoptos is as well marker s involved i n ER  
negativ e bre ast cancer developm ent pathway , including the src and mTOR pa thway will be 
evaluated using the re verse phas e protein m icroarr ay (RPP M) method :  Epithelial cell clusters 
prepared from b reast FNAs are microdissected u sing an Aut oPix Autom ated Laser Capture 
Microscope. To ensure that we d istinguish 1) epithelial cells versus stromal cells, and 2) identify the 
degree of cytolog ical atypia, slides will b e pho tographed b efore m icrodissec tion. As in prelimi nary 
data, 100 total and phosphoproteins w ill be pro filed. Total pro tein concentrat ions  will be assessed by 
Spyro Ruby fluorescent staining ( 22), ( 23). RPP M will be performed using MicroVig eneTM imag e 
Proprietary Information of MD Anderson
18    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 analysi s software (24). Arrays will be scanned, spot intensity normalized, and st andard si ngle value 
will be generate d for  each sample (Image Quant v5.2). S pot int ensity will be in tegrated and 
backg round int ensity calcula ted (JMP v5.0, SA S). Key techno logical component s of RPP M off er 
uniqu e advantages over tissue o r antibody ar rays(22), (23).  RPP M uses dena tured lysate so antigen 
retrieval, whi ch is a limitation fo r tissue arrays, is not a prob lem. Secondly , each  sample is pr inted 
on the ar ray in serial dilu tion, providing  an internal s tandard. Fina lly, RPP M does not r equire direct 
labeling of the sample, thus im proving reproducibility, sensitivity, and robus tness. 
 
Serum  IGF pathway markers: IGF-1 and IGFB P3 are p otential intermediate biomarker s for short 
term bre ast cancer prevention trials (25), (26), {Arun, 2011 #3436}. 
 
Non- fasting  blood sample o f approximately 10 ml w ill be draw n at the baseline vis it and at 3 months, 
using ster ile needle s into a 10 ml speckled red top SST tube. The blood in sp eckled red top tube s will 
be proce ssed at  the clin ic site by standi ng for 2 0-60 m in to c lot, then spinning fo r 20 minutes at 3200 
rpm. Serum  will be aliquotted into 3 tube s (1-2.0 ml each ), and p laced in a -70º C fr eezer.
Proprietary Information of MD Anderson
19    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 Table 1. SCHE DULE OF EVENTS  
 
Evaluation/Procedure  Registration  Baseline  Month 1h Month 2h Month 3 / 
Early 
Terminationh 
Informed Consent  Xg     
Assess Eligibility  X X    
Medical History   X    
Physical Exam   Xf    
Vital Signs   X    
Height and Weight   X    
Laboratory Tests   Xa    
EKG  X    
Mammogram   Xb    
Gynecologic  
Evaluation   Xe    
Pregnancy test   Xc    
Breast FNA   X   X 
Blood Biomarkers   X   X 
Concomitant  
Medications   X Xd Xd X 
Dispense Study  
Agent   X    
Collect Study Agent     X 
Review Diary   X Xd Xd X 
Adverse Events   Xd Xd X 
Nurse telephone 
follow -up   Xd Xd  
 
a = N ormal CBC , platelet count, e lectroly te, Magnesium,  liver panel, cre atinine wi thin last 3 mo nths and 
EKG wi thin one month pri or to randomization 
b = N ormal mammogram w ithin last 12 months prio r to rando mization 
c = N egativ e pregnancy  test within 14 days prior to r andomization or sta rt of the study agent , if 
applicable.   
d = Dur ing nurse phon e call 
e = Gynecology eval uation within th e last 5 y ears prior to randomization. Participants with a prior history 
of hysterectomy alone, hysterectomy and bilateral salpingo- ooporectomy, or bilateral salpingo-
ooporectomy alone are exempt from this requirement.  
f = N ormal physical ex am within l ast 12 months p rior to randomization 
g = Informed consent  is valid w ithin 30 days only pr ior to th e study drug; otherwis e, a new  
informed consent s hould be obta ined before reassessing the subject for protocol e ligibility  
h = A window of +/- 7da ys is allowed for these visits 
 
 
Proprietary Information of MD Anderson
20    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 8. CRITERIA F OR EVALUATION AN D ENDPOINT  DEFINITION 
 
Study endp oints in our study consist of biomark er chang es in b reast tis sue and serum. Sam ples for  the 
evaluat ion of thes e marker s will be obtained pre study initia tion and at 3 months (+/- 7 days). T he specif ics 
are descr ibed below. 
 
8.1 Primary Endpo int 
 
The primary g oal is to evaluate Dasat inib induced  reduction of prolife ration. Ki- 67 will be m easured in 
baseline and month 3 contrala teral breast FNA samples. 
 
8.2 Secondary Endpo ints 
 
8.2.1 Cytology: Chang es in cytology in base line and  month 3 F NA sam ples wi ll be evalua ted.  The 
cytology cr iteria used for th e interpretation of the smear a re sim ilar to the 1997 consensu s criteria 
published by the N ational Cancer  Institute: Inadequat e cellular materi al for diagnosis, normal 
epithelial cells, atypical hy perplasi a, suspicious and malig nant. 
 
8.2.2 Prolifera tion and apoptos is analysis of FNA samples: EGFR, P-EGFR, bcl-2, CC3 expr ession 
in FNA sa mples at baseline an d at month 3 (+/- 7 day s) will be evalua ted by  immunohis toche mistry 
(IHC). Scoring w ill be perform ed by  Dr. Yun Gong. 
 
8.2.3 Proteomic profile analysi s of FNA samples: Src, AMPK  and M-TOR rela ted pathway s will be 
evaluated in FNA sa mples obtained  at baseline and at 3 months af ter dasat inib treatm ent. Samples wil l 
be eval uated by D r. Seew aldt. 
 
8.2.4 Serum marke rs: IGF pathw ay (IGF-I, IGFBP-1, IGFBP-3) at  baseli ne and at 3 months will 
be eval uated in D r. Arun’s laboratory. 
 
8.3 Off Agent Criteria 
 
Participants may stop tak ing study ag ent for the following reasons: co mpleted the proto col-prescribed 
intervention, adverse ev ent or seri ous adver se ev ent, inadequa te agent su pply, non complianc e, 
concom itant medications, or medical contraindication. Participan ts will co ntinue to be follow ed, if 
possible, fo r safety reasons and in order to collect endpoint data according to the s ched ule of events. In 
case particip ants will be off agent but have tak en at least 1 dose of dasa tinib and underg o a month 3 FN A, 
they will be statis tically evaluable fo r biomark er endpoint. 
 
8.4 Off Study Cr iteria 
 Participants may go ‘of f-study’ for the following reasons: the protocol i ntervention and any protocol- 
required follow-up period i s completed, advers e event/serious adverse event, lost to fol low-up, non- 
complianc e, concomitant medication, m edical contraindication, r ecurrent d isease, w ithdraw co nsent, or 
death. 
 
9. S
PEC IMEN MANAG EMENT 
 
9.1 Labora tories 
 
9.1.1 Obtaining and p rocessing of br east FNA sa mples and cy topathologic interp retation w ill be 
perform ed, e valua ted and st ored at the MD Anderson Cance r Center Cytopatho logy laboratory 
(Address: U T M. D. Anderson Cance r Cente r Department of Cytopathology U nit 53, 1515 
Holcom be Bl vd, R oom G3.3628, Houston, Texas 77030-3721) FNA sam ples in CytoLy t 
Proprietary Information of MD Anderson
21    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 labeled w ith the study ID from  DUKE will be sent to t he MD Ande rson Cancer Center 
Cytopathology labora tory (same addre ss), fo r centralized cytology review by  Dr. Yun Gong 
 
9.1.2 KI-67, EGFR, P-EGFR, bcl-2, CC3 p-Y418- Src, p -Y-118- Paxill in ex pression in FNA sam ples 
will be performed by IHC analysis at MD Anderson Ca ncer C enter, Pa thology 
Immunohistoc hemistry Core Lab oratory for centraliz ed staining. Sco ring w ill be performed by 
Dr. Yun Gong. 
 
9.1.3 Proteom ic profile analysi s involv ing the src, AMPK and mTOR pathw ay in FNA sam ples that 
are labeled as in sec tion 7.5.5 will be perform ed by D r.Victori a Seewa ldt at Duk e Uni versity 
(Shipping address: Duk e universi ty Medical Cen ter, 2301 Erwin Rd, Rm 221A MSRB, 
Durham, NC 27710) 
 
9.1.4 IGF path way (IGF-I, IGFBP-1, IGFBP-2), leptin, adiponek tin at b aseline and  at 3 months wil l 
be evalua ted in Dr .Arun’s laborato ry (1515 P ressler Street, Unit 1354, Houston, TX 77 030). 
 
9.1.5 Routin e laborato ry tests for eligibil ity at ba seline (Section 7.2 ) will be perf ormed at  each 
Institution’s standard laboratory. 
 
9.2 Collection and Hand ling Proced ures 
 
Fine Ne edle Asp iration (FNA): 
 
We wi ll obtain p re and po st dasa tinib treatment FNA from breast  tissue at baseline and at 3 months (+/- 7 
days) from each p articipant as descr ibed in sec tion 7.6. An averag e of 6-8 sep arate needle passes will be 
performed i n 1 breast. The materi al obta ined by fine nee dle aspiration is rinsed into the CytoLy t fixative 
solution. T he proce dure is repeated, using a disposab le needle and a syringe. Once cells are in CytoLy t, the 
cells will be fixed and the vial can be le ft in room temperatur e until next step.   Cel ls in the CytoLyt ar e 
spinned  down and an aliquot of the sediment is re-suspend in Pr eserv eCyt so lution and then thin-layered 
slides are prepared using the ThinP rep Pro cessor.  Th in-layer slide is fix ed w ith 95% a lcohol and sta ined 
with Papanicola ou and cellulari ty of this slide is evaluated.  Th e cells in the re maining sediment will be re-
suspended  in PreserveCyt so lution and thin-layered slides wi ll be prep ared. Slides will be fix ed wi th 95 % 
alcohol and ai r-dried and sto red at -80⁰C f or the analysis of proposed marker s.  One F NA pass w ill be 
placed in saline solution and  frozen at  -80⁰C.  A pre printe d label wi ll be att ached to identify all sample 
vials. 
 
Blood Co llection: 
 
Peripheral blood will be obtained by venipuncture at baseline and at 3 months (+/- 7 days). Twenty ml blood 
will be collected in 2 red top tubes for biomarkers analysis (baseline and at 3 months (+/- 7 days)) and be processed within 24hrs of collection. If blood is not processed within 24hrs, a new sample will need to be collected and processed correctly.  
 
For th e purpose of tracking samples:  A pre-print ed label will b e atta ched  to ident ify all sa mple via ls. 
Blood wi ll be s tored at -20⁰C, se rum will be st ored at -80⁰C.  
 
9.3 Tissue Bank ing 
 
If the pa rticipants ag ree, unused F NA samples without participant identifiers (except study P ID) will be 
placed into 1.5 ml RNA later (Am bion). This will b e held at r oom temperatu re for 15 m inutes  then snap 
frozen and s tored at - 80⁰C in ou r (MDACC) Inst itutional Tissue Bank  Core F acility/Cytopathology Lab. 
 
Unused serum w ill be stored at -80⁰C in  Dr. Arun’s Laboratory. 
 
Proprietary Information of MD Anderson
22    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 10. REPORT ING  ADV ERSE EVENTS  
 
DEFINITI ON: An adver se event (A E) is any untoward medical occurrence in a study participant.  An A E 
does not ne cessarily have a causal relationship w ith the treatm ent or study participant.  An A E can 
therefo re be any  unfavorable and unin tended sig n (including an ab norm al laborato ry finding), symptom, or 
disease temporally associated with par ticipation i n a study, whether or not related to that partic ipation. Th is 
includes all deaths that occur whi le a particip ant is on a study. 
 
A list of adverse events that  have occu rred or might oc cur (Repor ted Adver se Events and Potential Risk s) 
can be found in Sec tion 6.2, Phar maceutical Informati on as we ll as the Inv estigator Brochur e or package 
insert. 
 
10.1 Adverse Events 
 
10.1.1  Report able Ad verse Ev ents 
 
All adverse events that occur after the inform ed cons ent i s signed (including run-in) m ust be 
recorded on the adverse ev ent CRF (p aper and/or el ectronic) wheth er or not relat ed to st udy agent. 
 
10.1.2  AE Da ta Elements: 
• AE repo rted date 
• AE Ve rbatim Term 
• CTCA E Category (v4.0) 
• CTCAE Term (v 4.0) 
• Event ons et da te and ev ent ended date 
• Severity grade 
• Attribution to study ag ent (relatedness) 
• Whet her or not the ev ent was reported as a Serious Adverse Event (SAE) 
• Whet her or not the participant dropped due to the adver se event 
• Action taken  with the study ag ent 
• Outcom e of the event 
• Comm ents 
 
10.1.3  Severity of A Es 
 
10.1.3.1 Advers e event will be id entified using the N CI Comm on Term inolo gy C riteria for 
Advers e Events (CTCA E) version 4.0.  The CTCA E pro vides descr iptive term inology and a 
grading scale for each adver se ev ent listed.  A copy of the CTCA E can be found a t 
http://c tep.cancer.gov.  
 
AEs will be assessed according to the CTCA E grade associated with the AE te rm.  AEs 
that do not have a co rresponding CTCA E term will be assessed acc ording  to their impact 
on the particip ant’s ability to perform daily activities as fo llows: 
 
 
Grade  Seve rity Description 
1 Mild • Barely noticeable, does not influence fun ctioning 
• Causing  no limitations of usual activities 
2 Mod erate • Makes participant uncomforta ble, influences functioning 
• Causing  some limitations of usual activities 
3 Severe • Severe discomfort, treatment needed 
• Severe and  undesi rable, causing inabi lity to carry out 
usual ac tivities 
Proprietary Information of MD Anderson
23    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 4 Life threatening • Immediate risk of death 
• Life threatening or disabling 
5 Fatal • Causes  death of the participant 
 
10.1.4  Assessment of  relationship of AE to treatm ent 
 
The possibil ity that the adverse event is relate d to study drug w ill be classif ied as 
one of the  following:  unrela ted, unlikely, possible, p robable, definite. 
 
10.1.5  Follow-up of A Es 
 
All AEs, including lab abn ormalit ies that in the opinio n of t he investigator are 
clinically significant, will be  followed acc ording to good m edical pr actices and 
docum ented as such.  
 
10.2 Serious Adv erse Events 
 
10.2.1  DEFINITI ON: ICH Guideline E2A and Fed. Reg. 62, Oct. 7, 19 97 define serious 
adverse events as those events, occurring at any dose, wh ich m eet any of the 
following criteri a: 
• Results in de ath 
• Is life threatening ( Note: the term life-threa tening refers to an e vent in 
which the pat ient was at r isk of de ath at th e time of the e vent; it does n ot 
refer to an e vent 
which hypothet ically mi ght have c aused  death if it were more s evere). 
• Requir es inpatient hospitalization o r prolongation of ex isting hospitalization 
• Results in persis tent or si gnificant disability/incapacity 
• Is a con genital abnormal ity/birth defect 
• Events that may not meet these cr iteria, but which the investigator finds very 
unusual and/o r potentially serious,  will also be  reported in the same manner 
 
 
 
10.2.2  Partic ipating orga nization will comply with applicable reg ulatory requirements 
related to rep orting SAEs to  their IRB. 
 
 
11. STUDY MON ITORI NG 
 
Please refer to Appen dix A. 
 
 
12. STAT ISTICAL CON SIDERA TIONS  
 
12.1 Study D esign/En dpoints 
 
This is a ph ase I biomarker modulation s tudy of dasatinib in breast tissue of wom en who are a t 
increased risk. To have a total of 60 particip ants, we have built in a 10% attrition rate and will accru e 66 
partic ipants. Pa rticipants will be randomized i nto two treatment groups and one no treatment control group 
(N=15).  The two treatment groups are 40 mg qd (N=30), and 80 mg qd (N =15)  of da satinib. The primary 
endpoi nt will be the chan ge in Ki-67 bef ore and after 3 months of dasatinib treatment i n bre ast tissue of 
high- risk women. Ki-67 is measured as a continuous variable and a one-wa y ANOV A followed by  
Dunnett ’s multiple comparison test comparing the chan ge of Ki-67 of each of the th ree tr eated groups 
with control. The purpose of this s tudy is to determine the m inimum biolo gical effectiv e dose, wh ich is 
Proprietary Information of MD Anderson
24    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 defined as the lowest dose whe re the c hange of Ki-67 is significantly different from that in the control group. 
Based on the r ecent report by Fabian  et al. (26), the bas eline Ki-67 value (in % o f cell positiv e) is about 
6.5% w ith a range betwee n 0%  and 40%. 
 
12.2 Samp le Size/Acc rual Rate 
 
The p rimary endpoi nt is the change of Ki-67 be tween pre-treatment and p ost treatment. Relativ e difference 
of the Ki-67 change between groups is used to evalua te the treatm ent effect. We assume that the  change 
of Ki-67 after the tr eatment is positively associated w ith the do se level. Mo nte Carlo simulations have been 
performed to analyze the power for the m ultiple comparisons using the Dunnett’ s two-sided test procedur e, 
where the sample mean in each treatment group is compar ed with the sampl e mean in the control group. 
A one-way design w ith the sample size of 15 and 30 in the two treatment g roups and 15 in the contr ol 
group can achieve an any-pair pow er of 0.87 assuming the effect size of 1 and  the signifi cance level of 
0.05. The any-pair pow er is defined as the prob ability of det ecting th e significant diffe rence be tween any 
treatment groups and t he cont rol group. T he effect size is t he standardiz ed mean differen ce betw een the 
treatment group and the control g roup, w hich is the rat io of detectable diffe rence betw een the two groups 
and the common standa rd dev iation w ithin groups. Base d on pr eliminary da ta (26), th e standard de viation 
is about 10 % fo r a single Ki-67 m easure at the  baseline or a fter treatm ent. Under a co nservative assumption 
that the correlation coef ficient between the bef ore and a fter treatment Ki-67 is 0.5, the standa rd deviation 
of the Ki-67 modulation is also 10%. Therefore, an effect size of 1 corr esponds to a Ki-67 chan ge of 10% 
and an effect size of 1.2 corresponds to a Ki-67 change of 12%. With 30 and 15 participan ts in the two 
treatment groups, we w ill have at least 87% po wer to detect an effect size of  1.0 o r larger . Power calcula tions 
were co mputed  in PAS S 2005. 
 
 
Effect Size Power to detect significance difference between any  pairs 
0.8 0.70 
1.0 0.87 
1.2 0.96 
 
In addi tion to the abov e analysis, if the data devia te from G aussian dist ribution, proper tr ansformation w ill 
be sought and nonparamet ric methods will be applied to provide vali d data analysis. Analysis of 
covariance (ANCOVA ) adjusted by base line covariates associated wi th Ki-67 will be u sed to increase the 
statist ical powe r for identifying biolo gically effective treatments 
 
12.3 Randomiz ation and Stratification  
 
No stratif ication f actors will be u sed in this rela tive small phase I study (compar ed to pha se III). A random 
perm utated block design with a block siz e of 4 or 8 wi ll be u sed to ensure balan ce in randomization. 
 
12.4 Primary Endpoint  
 
The primary endpoint wi ll be th e change in Ki-67 befo re and after 3 m onths o f dasatinib treatm ent. As 
indica ted in Section 13. 1, a one-way ANO VA by Dunnett ’s multiple comparison t est will be  appl ied for 
analyzing the primary endpoint. 
 
12.5 Secon dary E ndpo ints 
 
Seconda ry endpo ints include evalua tion of other proliferation and ap optosis marker s (EGFR, CC 3, bcl-2, 
ER, p21, p27), metabo lites of th e drug, and HMG-CoA redu ctase genotype. Thes e will be exploratory 
endpoint s performed and analyzed as sam ples permit. D escriptive statis tics will be computed  to estimate 
the distribut ion of the b iomarker s and the ch ange of biomark er values be fore and after treatm ent. 
Explorato ry data analysis will be  appl ied to check  for outlie rs and to have a p relim inary evaluation o f the 
treatm ent effect by dose an d associat ion a mong various var iables. Oth er standard statist ical methods for 
Proprietary Information of MD Anderson
25    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 analyzing continuous and categorical da ta will be applied whenev er appropria te. 
 
12.6 Reporting and Exclusi ons 
 
All evalu able participants in the study w ill be evaluated for toxicity and effic acy. 
 
12.7 Evaluat ion of Toxicity 
 
All participants will be evaluab le for toxicity from  the time of randomization. 
An event with an attribution of po ssible, probably , or defini te is considered related. 
 
Bayesian  toxici ty monitori ng schem a will be used to m onitor t oxicity profile in the treatment a rms. Each 
treatment arm will be m onitored separately for to xicity.  “Se vere Tox icity” is def ined as grade 3  or 4 
toxic ity related to the current dos e level. Th e toxic ity monitoring w ill start a fter enrolling at least 3 
participa nts in each do se level.  I f a dose level is terminated due to the tox icity, the rest of the participan ts 
will be  assig ned to t he lowe r dose level s only. 
We deno te the probability of toxicity for each do se level as θi, i=1, 2 an d assume that no toxicity is 
observed in the control group. Th e treatment wi ll be stopped ear ly if 
 
Pr[θi >0.10 | data ] > 0. 85, i=1, 2 
 
for dose level i and  higher dose level s.  In othe r words , the trial wi ll be terminat ed if there is a greater than 
85% chance to observ e more th an 10% toxicity at 40mg level.  We  assum e that the pri or distribut ion of θi 
follows a Beta (0.05, 0.95), which im plies that the pr ior toxicity rate is 5% for e ach dose level. The c hoice 
of the paramete rs are based on pr ior data suggesting that about 5% o f toxicity is expected in this drug and 
higher than 10% toxici ty is consi dered unac ceptable. 
 
The st opping boundary and the p robability of ea rly stopping are presented in Tabl es 1 and 2 below. 
 
The t rial wi ll be monito red for each dose level accordi ng to the  following stopping boundari es for se vere 
toxicity. 
 
Table 1. Toxic ity Monitoring Boundari es 
 
Among number of 
Participants Recommend stop ping dose levels if 
number of sever e toxici ty 
obser ved >= 
3-7 2 
8-14 3 
15-21 4 
22-28 5 
29-30 6 
 
Table 2. Probabil ity of ea rly termination of a dos e lev el due to severe toxici ty 
 
True Se vere 
toxicity rate Proba bility of early 
terminating 40mg level 
(therefore the trial) Proba bility of 
early terminating 
80mg level 
5% 0.06 0.06 
10% 0.29 0.22 
15% 0.56 0.42 
20% 0.78 0.63 
Proprietary Information of MD Anderson
26    MDACC# 2010- 0794  
  Version Date: 6.13.17  
  
12.8 Evaluabili ty 
 
Participants who ar e randomiz ed to the treatm ent group will be  eval uable if they received at least 75% of 
their assigned d asatinib dose.  No imputation wi ll be performed on m issing data. 
 
 
12.9 Interim Analysis 
 
There will not be  interim analysis on eff icacy of the study. However , toxici ty will be m onito red c losely. 
 
 
 
13. ETHIC AL AN D RE GULATORY CON SIDERATIONS  
 
13.1 Institutional Review Boar d Approval  
 
Prior to initia ting the study the P rotocol Lead Inv estigator at the L ead Organization m ust obtain wr itten 
approv al to conduct the study from  the appr opriate IRB. Should chan ges to the st udy beco me neces sary, 
proto col amendments will be sub mitted to the I RB. 
 
 
13.2 Informed Cons ent 
 
All potential study particip ants will be given a copy of th e IRB-approv ed Informed Conse nt to rev iew. The 
investigator will explai n all aspec ts of the study in lay languag e and a nswer  all questions regar ding the 
study. I f the participant decides to participate in the study, he /she will be asked to sig n the Informe d 
Consent docum ent. The inform ed consent do cument is cons idered val id for 30 days from the pa rticipant’ s 
signature date to beg in treatm ent.  If treatment has n ot begun within 30 day s following the signatu re date 
listed on the informed consent do cument then  the particip ant must be rea ssessed for prot ocol eligibility 
and a new consent do cument completed. The study ag ent(s) will not  be released to a participant who h as 
not signed th e Informed Consent docum ent. Particip ants who  refuse to partic ipate or who wi thdraw f rom 
the study w ill be treated wi thout prejudice. 
 
Participants must be provided th e option to allow th e use of  blood sam ples, other body fluids, a nd 
tissues obtained during scheduled  testing, ope rative procedures, or other standa rd medical pr actices for 
further res earch purpos es. A  sepa rate signatu re area is required to allow particip ants to opt out of 
allowing ti ssue to be used for further resear ch. 
 
13.3 Other 
 
This trial will be cond ucted in compli ance w ith the protocol, Good C linical Practice (GC P), and the 
applicable regulatory requirements. 
 
REFERE NCES 
 
1. Fisher B, Cos tantino JP, Wickerham DL, Redmond C K, Kavanah M, Cron in WM, et al. Tamoxifen for  
prevention of b reast cancer: report of the Nation al Surg ical Adj uvant B reast and Bow el Proj ect P-1 Study. J 
Natl Cancer Inst. 1998;9 0:1371-88. 
2. Gail M, Brinton L, By ar D, Corel D, Green  S, Schairer C. Proj ecting ind ividualized  probab ilities of developing 
breast can cer for wh ite females who are b eing examin ed annually. J Nat Canc er Inst. 1989;81 :1879-86. 
3. McG uire WL, C lark GM. Prognos tic factors  and treatment d ecisions in axi llary-node-neg ative breast  
cancer. N Engl J Med. 1992;3 26:1756-61. 
4. Osborne C K, Zhao H, Fuqua SA. Select ive estrogen recep tor modulators: structure, function, and clinical use. J 
Clin Onco l. 2000;1 8:3172- 86. 
5. Thom as SM, Brugge J S. Cellular functions regulated  by Src family kin ases. A nnu Rev Cell Dev Biol. 
1997;13 :513-609. 
Proprietary Information of MD Anderson
27    MDACC# 2010- 0794  
  Version Date: 6.13.17  
 6. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of P KC alpha by ErbB 2 through Src promo tes 
breast cancer cell invasion th at can be b locked by combin ed treatment with P KC alpha and Src inhibitor s. 
Oncogen e. 2006;2 5:3286-95. 
7. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4:4 70-80. 
8. Wilson GR, Cram er A, Welm an A, Knox F, Swind ell R, Kawak atsu H, et al. Activated c-SRC in ductal 
carci noma in situ co rrelates  with high tumour g rade, high proliferation and HER2 positivity. Br J Can cer. 
2006;95 :1410-4. 
9. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, et al. Src promo tes estrogen-dependent es trogen 
recep tor alpha pro teolysis in human b reast cancer. J Clin I nvest. 2007;1 17:2205- 15. 
10. Hiscox S, Morgan L, Green  T, Nicholson R I. Src as a therapeu tic target in anti-hormon e/anti-growth fac tor- 
resistant b reast cancer. Endocr Relat Cancer. 2006;13 Su ppl 1 :S53-9. 
11. Fabian CJ, Kim ler BF, Elledge R M, Grizzle  WE, Beenken  SW, Ward J H. Mod els for early  
chem oprevention trials  in breast cancer. Hema tol Oncol C lin North Am. 1998;1 2:993- 1017. 
12. Dunn B K, Kramer BS, Ford  LG. Phase III, large-scale chem oprevention trials. Approach to chem oprevention 
clinical trials and ph ase III clinical trial of tamoxifen as a chem opreventive for b reast cancer--the  US Nation al 
Cancer Institute exper ience. Hem atol Oncol Clin No rth Am. 1998;1 2:1019- 36, v ii. 
13. Arun B, Valero  V, Cook E, Lammy J, Sm ith T, Ho rtobagyi G, et al. Phase II chem oprevention trial of  
celecox ib using du ctal lavag e. Breast Cancer Res and T reatmen t. 2003;71 :126a. 
14. Arun B, Valero  V, Logan C, Brog lio K, Rivera E, Brewster A, et al. Comparison of du ctal lavage and  random 
periareolar fine n eedle aspirati on as tissue acquisition meth ods in early breast can cer prevention trials. Clin  
Cancer Res. 2007;1 3:4943- 8. 
15. Rosen PP, Groshen S, Kinne DW, Hellman S. Con tralateral  breast car cinoma: an assessment of risk and  
prognos is in stage I (T1N0M0) and s tage II (T1N1M0) p atients with 20-y ear follow-up. Surgery. 1989;1 06:904-
10. 
16. Robinson E, Rennert G, Rennert HS, Neugut A I. Surviv al of first and s econd p rimary b reast cancer. 
Cancer. 1993;7 1:172- 6. 
17. Khan QJ, Kim ler BF, O'Dea  AP, Z alles C M, Sharma P, Fabian CJ. Mammog raphic dens ity does not correlate  
with Ki-67 exp ression or cytomorpho logy in benign breast cells obtain ed by random per iareolar fine n eedle 
aspiration from women at high risk for b reast cancer. Breast Cancer Res. 2007;9:R 35. 
18. Zalles C M, Kim ler BF, Simons en M, Clark JL, Metheny T, Fabian CJ. Comparison of cytomorpho logy in 
specimens obtain ed by random per iareolar fine n eedle aspiration and du ctal lavage from wom en at high risk for  
development of b reast cancer. Breast Cancer Res T reat. 2006;97:191-7. 
19. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Onco l. 
2005;23 :7212-20. 
20. Dowse tt M, Bundred NJ, Dece nsi A, Sainsbury RC, Lu Y, Hills  MJ, et al. Effect of R aloxifene on B reast  
Cancer Cell Ki67 and A popto sis: A Double-Blind, P lacebo-con trolled, Random ized Clini cal Trial in 
Postmen opa us al Patients. Can cer Epidemiol Biomarkers P rev. 2001;1 0:961- 6. 
21. Fabian CJ, Kim ler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, et al. Redu ction in pro liferation with  six 
months of letrozole in wom en on hormone replacement therapy. B reast Can cer Res Treat. 2007. 
22. Wulfkuhle JD, Liotta  LA, P etricoin EF. Proteomic applications for the early detection  of can cer. Nat Rev 
Cancer. 2003;3:2 67-75. 
23. Gulmann C, Sheehan KM, Kay EW, L iotta LA, P etricoin EF, 3rd. A rray-based proteomics: ma pping  of 
protein circuitries  for d iagnost ics, prognos tics, and therapy gu idance in cancer. J Pathol. 2006;208:595-606. 
24. Latta EK, Tjan S, Park es RK, O'Malley FP. The ro le of HER2/neu overexp ression/ampli fication in the 
progression of du ctal carcinoma in situ to invasive carci noma of the b reast. Mod P athol. 2002;15 :1318- 25. 
Proprietary Information of MD Anderson
33 
    MDACC# 2010 -0794  
  Version Date: 6.13.17  
  
25. Schapira DV, Kum ar NB, Lym an GH. Obesity, body f at distribution, and sex hormon es in breast cancer 
patients. Can cer. 1991;6 7:2215- 8. 
26. Fabian CJ, Kim ler BF. Use of biomarkers for b reast cancer risk asse ssment and p revention. J Steroid 
Biochem Mol B iol. 2007 ;106:31- 9. 
Proprietary Information of MD Anderson